TITLE

XECHEM/SHANGHAI FUDAN TO DEVELOP NEW PACLITAXEL ANALOGS

PUB. DATE
May 2001
SOURCE
Worldwide Biotech;May2001, Vol. 13 Issue 5, p2
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports the cooperation agreement of Xechem International Inc. and Xechem Pharmaceutical China Ltd. with the Shanghai Fudan Taxusal New Technology Co. Ltd. to develop paclitaxel soluble analogs and other natural products isolated from Chinese traditional medicines.
ACCESSION #
4425595

 

Related Articles

  • HEMONC TODAY's blogger talks about early stop to ESCAPE trial. Campbell, Toby // Hem/Onc Today;3/10/2008, Vol. 9 Issue 4, p4 

    The author discusses the early closing of Bayer's phase-3 ESCAPE (Evaluation of Sorafenib, Carboplatin, And Paclitaxel Efficacy) trial evaluating the role of sorafenib in combination with chemotherapy in metastatic non-small cell lung cancer (NSCLC). He reveals the reason for the closing. The...

  • BU team part of anti-cancer boost. Spohr, George // Business Journal (Central New York);2/27/2004, Vol. 18 Issue 9, p1B 

    The article focuses on the breakthrough made in the anticancer drug Taxol, by a team of Binghampton University. Taxol generates $15 billion annually in the United States for Bristol-Myers Squibb Co. Similar generic drugs generate several hundreds of millions of dollars more, according to the...

  • Multicompartimental Nanoparticles for Co-Encapsulation and Multimodal Drug Delivery to Tumor Cells and Neovasculature. Mendes, Lívia; Gaeti, Marilisa; Ávila, Paulo; Sousa Vieira, Marcelo; Santos Rodrigues, Bruna; Ávila Marcelino, Renato; Santos, Lílian; Valadares, Marize; Lima, Eliana // Pharmaceutical Research;May2014, Vol. 31 Issue 5, p1106 

    Purpose: The purpose of this work was the development of a multicompartimental nanocarrier for the simultaneous encapsulation of paclitaxel (PTX) and genistein (GEN), associating antiangiogenic and cytotoxic properties in order to potentiate antitumoral activity. Method: Polymeric nanocapsules...

  • A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Hamaguchi, T.; Kato, K.; Yasui, H.; Morizane, C.; Ikeda, M.; Ueno, H.; Muro, K.; Yamada, Y.; Okusaka, T.; Shirao, K.; Shimada, Y.; Nakahama, H.; Matsumura, Y. // British Journal of Cancer;7/16/2007, Vol. 97 Issue 2, p170 

    This phase I study was designed to examine the maximum tolerated dose (MTD), the dose-limiting toxicities (DLTs), the recommended dose (RD) for phase II, and the pharmacokinetics of NK105, a new polymeric micelle carrier system for paclitaxel (PTX). NK105 was administered as a 1-h intravenous...

  • Role of tumor necrosis factor alpha-induced protein 1 in paclitaxel resistance. Zhu, Y.; Yao, Z.; Wu, Z.; Mei, Y.; Wu, M. // Oncogene;6/19/2014, Vol. 33 Issue 25, p3246 

    Paclitaxel has been extensively used as an antitumor drug to treat a broad range of epithelial cancers, including breast and cervical cancers. However, the efficacy of this drug is greatly limited by the development of acquired resistance. Identification of the underlying resistance mechanisms...

  • American Pharmaceutical Partners: regulatory boost for promising breast cancer drug.  // PharmaWatch: Cancer;March 2003, Vol. 2 Issue 3, p16 

    Reports on the result of the clinical trial of ABI-007, a cremophor-free nanoparticle paclitaxel developed by American Pharmaceutical Partners Inc. for the treatment of metastatic breast cancer in the U.S. Efficacy of the treatment; Tolerability in higher doses; Implications of the drug's...

  • Private Sector Gets Pat on Back for Drug Development Efforts. Hollingsworth, Catherine // BioWorld Today;6/26/2008, Vol. 19 Issue 124, p1 

    The article focuses on the private sector's role in pharmaceutical research and development (R&D). It is mentioned that private companies have been funding research efforts on drug development and innovation which resulted to important drugs like Taxol, Gleevec, and Epogen. Biotechnology...

  • OTHER NEWS TO NOTE.  // BioWorld Today;7/15/2008, Vol. 19 Issue 136, p2 

    This section offers news briefs on the biopharmaceutical industry as of July 15, 2008. The China State Food and Drug Administration has given its approval for the marketing of Abraxane Paclitaxel for Injection from Abraxis BioScience Inc. Preclinical results for naltrexone for extended-release...

  • Downstream reactions and engineering in the microbially reconstituted pathway for Taxol. Jiang, Ming; Stephanopoulos, Gregory; Pfeifer, Blaine // Applied Microbiology & Biotechnology;May2012, Vol. 94 Issue 4, p841 

    Taxol (a trademarked product of Bristol-Myers Squibb) is a complex isoprenoid natural product which has displayed potent anticancer activity. Originally isolated from the Pacific yew tree ( Taxus brevifolia), Taxol has been mass-produced through processes reliant on plant-derived biosynthesis....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics